{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:41:54Z","timestamp":1790379714563,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In September 2016, ponatinib was approved in Japan for the treatment of patients with chronic myeloid leukemia with resistance\/intolerance to prior tyrosine kinase inhibitors and patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a post-marketing all-case surveillance to study the safety and efficacy of ponatinib in clinical practice, focusing on arterial occlusive events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 724 patients were collected for 2\u00a0years from the initiation of ponatinib. The arterial occlusive events were reported in 6.49% (47\/724) with an exposure-adjusted incidence rate of 6.8\/100 person-years. The risks associated with arterial occlusive events were age and comorbidities including hypertension and diabetes. At 104\u00a0weeks, the cumulative major molecular response rate in patients with chronic-phase chronic myeloid leukemia was 67.2% and the complete cytogenetic response in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia was 80.0%. Furthermore, the estimated 1-year overall survival rate was 98.5% for chronic-phase chronic myeloid leukemia and 68.6% for Philadelphia chromosome-positive acute lymphoblastic leukemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This surveillance demonstrated that ponatinib has a favorable safety and efficacy profile in Japanese patients and also showed the necessity of closely monitoring arterial occlusive events in older adults and patients with predisposing factors for atherosclerosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae061","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:47:00Z","timestamp":1715784420000},"page":"930-938","source":"Crossref","is-referenced-by-count":11,"title":["Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan"],"prefix":"10.1093","volume":"54","author":[{"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[{"name":"Akita University Graduate School of Medicine Department of Hematology, Nephrology and Rheumatology, , Akita , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Aiiku Hospital Department of Hematology, Blood Disorders Center, , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[{"name":"Tokai University Hospital Department of Cardiology, , Isehara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Kurume University School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine, , Kurume , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare Department of Lymphoma\/Hematology Center, Mita Hospital, , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Masunari","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishibayashi","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co., Ltd , Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[{"name":"Tokyo Medical and Dental University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024081411152186000_ref1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"2024081411152186000_ref2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"2024081411152186000_ref3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"2024081411152186000_ref4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"2024081411152186000_ref5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","article-title":"Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study","volume":"106","author":"Tojo","year":"2017","journal-title":"Int J Hematol"},{"key":"2024081411152186000_ref6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2024081411152186000_ref7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2024081411152186000_ref8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect Clin Res"},{"key":"2024081411152186000_ref9","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","article-title":"Real-life experience with ponatinib in chronic myeloid leukemia: a multicenter observational study","volume":"18","author":"Shacham-Abulafia","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024081411152186000_ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp Hematol"},{"key":"2024081411152186000_ref11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00277-021-04507-x","article-title":"Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice\u2014data from a Belgian registry","volume":"100","author":"Devos","year":"2021","journal-title":"Ann Hematol"},{"key":"2024081411152186000_ref12","author":"International conference on harmonisation harmonaised tripartite guidline E2A","year":"1994"},{"key":"2024081411152186000_ref13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12185-020-02964-0","article-title":"JSH practical guidelines for Hematological malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN)","volume":"112","author":"Shimoda","year":"2020","journal-title":"Int J Hematol"},{"key":"2024081411152186000_ref14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2024081411152186000_ref15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"2024081411152186000_ref16","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"2024081411152186000_ref17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/8\/930\/58816371\/hyae061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/8\/930\/58816371\/hyae061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:15:39Z","timestamp":1723634139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/8\/930\/7673536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae061","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,15]]}}}